Abstract
(Int J Obstet Anesth. 2019;39:12–21) Remifentanil patient-controlled analgesia (PCA) has been used for ∼20 years during labor as an alternative analgesic approach. While many units utilize this analgesic option in patients who cannot receive neuraxial analgesia, some offer it routinely to their laboring patients. There are some potentially serious side effects of remifentanil PCA, such as respiratory depression and hypoxemia. Swiss researchers developed the RemiPCA SAFE Network in 2009 when the analgesic technique became available in their country. The purpose of the network was to monitor PCA use and assess maternal and neonatal outcomes. While initially developed for Swiss facilities, the network later allowed obstetric units from other countries to participate and provide their data. Data collected by the network helps individual facilities to evaluate their performance and allows the network committee to assess the overall outcomes of remifentanil PCA for labor. The goal of the current audit study was to accurately outline the quality assurance system used by the network and analyze outcomes on remifentanil PCA effectiveness and safety based on the data collected.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.